Biologics for Severe Asthma: Beyond Singulair

When inhaled corticosteroids, Singulair, and antihistamines fail, what's next? This episode maps the biologic and small-molecule landscape for severe asthma — anti-IgE, anti-IL-5, and anti-IL-4/IL-13 therapies. Learn how omalizumab, mepolizumab, benralizumab, and dupilumab target specific inflammatory mediators, how to match patients to the right biologic using biomarkers like IgE, eosinophils, and FeNO, and what practical factors — dosing frequency, comorbidities, lifestyle — tip the scales in clinical decision-making.